GCC Organ Transplant Nursing Guide

🧬HLA Matching & Compatibility

HLA System Basics

Human Leukocyte Antigens — encoded on chromosome 6
Class I: HLA-A, B, C — expressed on all nucleated cells
Class II: HLA-DR, DQ, DP — expressed on APCs
6 key loci assessed: A, B, C, DR, DQ, DP
Better HLA match → lower rejection risk and better long-term graft survival
Zero-mismatch kidney grafts have significantly better outcomes

ABO Compatibility

Standard rule: same as blood transfusion compatibility
O = universal donor; AB = universal recipient
ABO incompatible (ABOi) transplants possible with desensitisation (rituximab + plasmapheresis)
ABOi requires higher immunosuppression burden
Used in living donor programmes when no compatible donor available

Panel Reactive Antibodies (PRA / cPRA)

PRA Definition

Percentage of panel donors against whom the recipient has preformed antibodies. Higher PRA = harder to find compatible donor and higher rejection risk.

cPRA (Calculated PRA)

More precise — calculates percentage of donors whose HLA antigens match recipient's unacceptable antigens. cPRA >80% = highly sensitised, priority listing in many systems.

Sensitising Events

Previous transplants
Blood transfusions
Pregnancies
Infections (some)

🔬Crossmatch Testing

Method	Mechanism	Sensitivity	Use
CDC Crossmatch Complement-Dependent Cytotoxicity	Recipient serum + donor lymphocytes + complement → cell lysis if antibodies present	Lower — detects only complement-fixing IgG	Traditional standard; positive = contraindication to proceed
Flow Cytometry Crossmatch (FCXM)	Fluorescence-labelled anti-human IgG detects antibody binding to donor T/B cells	Higher — detects low-level DSA	More sensitive; positive FCXM with negative CDC is a relative contraindication
Virtual Crossmatch	Compare recipient's anti-HLA antibody profile (SAB assay) against donor HLA typing	High — no live donor cells needed	Used for deceased donors; speeds organ allocation

⚠Positive crossmatch: Indicates preformed donor-specific antibodies (DSA). Proceeding typically leads to hyperacute or accelerated rejection. Desensitisation protocols may allow selected ABOi/DSA+ transplants in specialist centres.

🚨Rejection Types

Type	Onset	Mechanism	Features	Treatment
Hyperacute	Minutes to hours (intraoperatively)	Preformed antibodies → complement activation → thrombosis	Graft becomes mottled, cyanotic on table; rapid graft failure	No effective treatment — graft removal. Prevented by crossmatch
Acute Cellular (ACR)	Days to weeks (typically 5–90 days)	T-cell mediated attack on donor antigens	Fever, graft tenderness, rising creatinine (kidney), elevated LFTs (liver), reduced urine output	Pulse methylprednisolone; ATG if steroid-resistant
Acute Antibody-Mediated (AMR)	Days to weeks; can occur any time	DSA → complement activation → endothelial injury	C4d deposition on biopsy; microvascular inflammation; rising creatinine	IVIG, plasmapheresis, rituximab, eculizumab in refractory cases
Chronic Rejection	Months to years (>3 months)	Both immune and non-immune factors; ongoing low-grade injury	Gradual creatinine rise, proteinuria; interstitial fibrosis/tubular atrophy (IFTA) on biopsy	Optimise immunosuppression; manage BP and proteinuria; address non-compliance

📋Banff Classification (Biopsy-Proven Rejection)

Banff Grades — Kidney

Banff 1 (Mild ACR): Interstitial inflammation i2/i3, tubulitis t2/t3 — responds well to steroids
Banff 2A (Moderate): Mild-moderate intimal arteritis (v1) — pulse steroids ± ATG
Banff 2B (Moderate-severe): Severe intimal arteritis (v2) — ATG usually needed
Banff 3 (Severe): Transmural arteritis (v3) — poor prognosis, ATG + consider re-evaluation
IFTA: Interstitial Fibrosis and Tubular Atrophy — represents chronic injury regardless of aetiology

Banff — AMR Criteria

Histological evidence of microvascular inflammation (g+ptc >2)
Evidence of current/recent Ab interaction with endothelium (C4d+ or gene expression)
Serological evidence of DSA (HLA or non-HLA)
All 3 criteria required for definite AMR diagnosis
Active AMR: acute histology features present
Chronic Active AMR: features + chronic lesions (cg, cv, ci, ct)

🫘Pre-Operative Preparation

Pre-Op Nursing Checklist

Verify ABO/HLA/crossmatch results
Last dialysis session timing (within 24–48h)
Potassium ≤5.5 mEq/L before theatre
INR/coagulation profile; blood products available
Immunosuppression induction dose given (tacrolimus/MMF/prednisolone ± basiliximab/ATG)
IV access × 2 large bore; arterial line if haemodynamically unstable
Foley catheter + irrigation set ready
Ensure patient is euvolaemic — adequate fluid preloading
CMV/EBV status documented (donor and recipient)

Induction Immunosuppression

Basiliximab (Simulect): IL-2R antagonist — Day 0 and Day 4; low-risk patients
ATG (Thymoglobulin): T-cell depleting; high-risk, sensitised or DGF-risk patients
Methylprednisolone: High-dose IV intraoperatively
Tacrolimus: first dose 12–24h pre-op or at reperfusion depending on protocol
MMF: start day of transplant

💧Immediate Post-Op Monitoring (First 72h)

🎯 Target urine output: >1 ml/kg/hour — the single most important early post-op parameter. Oliguria requires immediate systematic assessment.

Haemodynamic Targets

MAP >70 mmHg (graft perfusion)
SBP typically 130–160 mmHg early
CVP 8–12 cmH₂O (adequate preload)
Avoid hypotension — aggressive fluid replacement
Avoid hypertension — can cause anastomotic stress

Fluid Balance

Replace urine output ml for ml (0.9% NaCl or Hartmann's)
Additional maintenance 30–50 ml/h
Monitor hourly UO closely
Avoid excessive fluid once good UO established
Daily weights; strict I&O charting

Labs & Monitoring Schedule

Creatinine + electrolytes q6–8h first 24h
FBC, LFTs, coagulation daily
Tacrolimus trough Level day 2
Doppler US of graft vessels within 24h
Drain output monitored hourly initially

Oliguria Assessment — STOP Approach

Step	Check	Action
S — System	Foley blocked/kinked?	Flush/unblock catheter; check tubing
T — Tank	Volume depleted? CVP low?	Fluid bolus 250–500ml; reassess
O — Output pressure	MAP <70? Cardiac output?	Vasopressors; echo if concerned
P — Plumbing	Vascular thrombosis? Ureteric obstruction?	Urgent Doppler USS; urology review

⏳Delayed Graft Function (DGF)

⚠DGF Definition: Need for dialysis within first 7 days post-transplant. Occurs in 20–50% of deceased donor kidneys. Associated with ischaemia-reperfusion injury, donor quality, cold ischaemia time.

DGF Risk Factors

Extended criteria donor (ECD) or DCD (donation after circulatory death)
Cold ischaemia time >24 hours
Donor age >60, diabetes, hypertension
Recipient BMI >30, PRA >50%
Haemodynamic instability at reperfusion

DGF Management

Continue dialysis as needed (haemo- or peritoneal)
Reduce/hold tacrolimus if levels supratherapeutic (minimise nephrotoxicity)
Serial biopsies if prolonged DGF to exclude rejection
Monitor Doppler for vascular patency
Expect recovery in days–weeks; some DGF lasts 4–6 weeks
Distinguish DGF from primary non-function (PNF) — no recovery

🔩Surgical Drains, Stents & Wound Care

Ureteric Stent (JJ Stent)

Placed at surgery to splint ureteroneocystostomy
Reduces ureteric leak and stricture risk
Typically removed at 4–6 weeks cystoscopically
Warn patient of urinary frequency, urgency, haematuria
Stent forgotten = encrustation, obstruction, UTI risk

Surgical Drain

Monitor drain output colour and volume hourly initially
Serous/serosanguineous: normal early post-op
Urine-like fluid: send for creatinine — if high = urine leak
Lymphatic fluid: lymphocoele (treat if symptomatic)
Drain removed when <30ml/day and no concerns

💊Tacrolimus Monitoring — Kidney

Phase	Target Trough (ng/ml)	Rationale	Nursing Action
0–3 months	8–12 ng/ml	Highest rejection risk period	Check trough q2–3 days; dose adjust per protocol
3–12 months	6–10 ng/ml	Reduced rejection risk, balance toxicity	Monitor monthly; check with any illness or drug change
>12 months (stable)	5–8 ng/ml	Minimise long-term nephrotoxicity	3-monthly monitoring; educate on adherence
Tacrolimus TOXICITY signs	Trough >15–20 ng/ml	Nephrotoxicity, neurotoxicity	Hold dose, medical review, check renal function and electrolytes

⚠Always draw trough BEFORE morning dose (12h post previous dose for BD dosing, 24h for OD extended-release Advagraf). Timing errors invalidate the result.

🫀Liver Transplant — Eligibility & Types

MELD Score & Listing

MELD = Model for End-Stage Liver Disease — predicts 90-day mortality
Listing threshold: MELD ≥15 (benefit of transplant outweighs surgical risk)
MELD >25: high urgency; MELD >35: very high mortality without transplant
Formula: 3.78×ln[bilirubin] + 11.2×ln[INR] + 9.57×ln[creatinine] + 6.43
MELD-Na adds serum sodium — better mortality prediction
Exception points added for HCC, hepatopulmonary syndrome

Transplant Types

Orthotopic LT (OLT): Native liver removed, donor liver in anatomical position — most common
Split Liver: Deceased donor liver split (right lobe → adult, left lateral segment → paediatric)
Living Donor LT (LDLT): Right lobe (65% liver mass) donated; critical in GCC where deceased donation is rare
Auxiliary Partial LT: Native liver left partially in situ — regeneration expected
Domino LT: Explanted liver (e.g., metabolic disease) re-transplanted

🩺Post-Op Priorities — Liver

Bile Output Monitoring

T-tube (if placed) — document colour, consistency and volume hourly
Normal: golden-yellow bile, 300–800ml/day
Dark bile: concentrated; monitor for obstruction
Absent bile: HAT or primary non-function
Bilious drain fluid: biliary leak
T-tube clamp trial before removal (Day 7–14)

Coagulation Management

New liver initially coagulopathic — monitor INR q4–6h
INR >2: FFP if bleeding; avoid routine correction (thromboembolism risk)
Fibrinogen <1.5 g/L: cryoprecipitate
Platelets <50: transfuse if active bleeding
Rising INR in stable patient = graft dysfunction
Improving INR = sign of graft function recovering

Glucose Control

Aim BGL 6–10 mmol/L (avoid hypoglycaemia)
IV insulin infusion if BGL >10 mmol/L
Hypoglycaemia: gluconeogenesis failure — sign of poor graft function
Steroid-induced hyperglycaemia very common
Monitor 1–2 hourly in ICU
Pre-existing diabetes requires close DAFNE/endocrine input

Graft Function Assessment

Parameter	Expected Trend	Abnormal Signal
AST/ALT	Peak day 1–3, then fall rapidly	Rising or persistently high = ischaemia, rejection, HAT
Bilirubin	Elevated initially, normalises over 7–14 days	Rising after day 3 = biliary complication, rejection
INR	Improves progressively over 3–5 days	Rising INR after day 3 = graft dysfunction
Glucose	Stable with insulin support	Hypoglycaemia unresponsive = PNF (primary non-function)
Bile production	Begins within hours; >100ml/day by day 2	Absent bile: HAT or PNF

🚑Hepatic Artery Thrombosis (HAT)

🔴HAT is the most feared early complication of liver transplantation. Incidence 2–5% adults, higher in paediatric. Without urgent intervention, results in graft failure within hours to days.

Clinical Features

Sudden rise in transaminases (AST/ALT)
Cessation of bile output; dark or absent bile
Rising INR, coagulopathy
Fever and sepsis (biliary ischaemia → necrosis)
Late HAT: biliary strictures, recurrent cholangitis
Can be clinically silent initially

Diagnosis & Management

Doppler USS: absent or reversed hepatic artery flow
CT angiography for confirmation
Urgent surgical thrombectomy/re-anastomosis if caught early
Radiological intervention (stenting) in selected cases
Re-transplantation if graft non-salvageable
Routine Doppler at 6h, 24h, 72h post-op in many centres

📐Biliary Complications

Biliary Leak

Incidence ~5–10%; T-tube exit site most common
Signs: bilious drain, bilioma, peritonitis
Diagnosis: ERCP, HIDA scan, drain fluid bilirubin
Management: ERCP + stent; surgical repair if large

Biliary Stricture

Anastomotic (most common) or ischaemic (non-anastomotic)
Ischaemic strictures = HAT, DCD, preservation injury
Signs: rising bilirubin, ALP, jaundice, cholangitis
Diagnosis: MRCP, ERCP
Management: ERCP dilatation + stenting; percutaneous if inaccessible

💊Calcineurin Inhibitors (CNI)

Tacrolimus (FK506, Prograf, Advagraf)

Mechanism: inhibits calcineurin → blocks IL-2 → T-cell suppression
Most widely used CNI worldwide
Monitoring: trough levels (see kidney tab for ranges)
Key side effects: Nephrotoxicity, neurotoxicity (tremor, headache, PRES), PTDM, hypertension, alopecia, hyperkalaemia
Drug interactions: azole antifungals ↑ levels; rifampicin ↓ levels; grapefruit ↑ levels
CYP3A4/P-glycoprotein substrate — numerous interactions

Cyclosporin (Ciclosporin, Neoral, Sandimmune)

Mechanism: same as tacrolimus (calcineurin inhibitor)
Less potent immunosuppression than tacrolimus
Monitor C0 (trough) or C2 (2-hour post-dose) levels
Key side effects: Nephrotoxicity, hypertension, hyperlipidaemia, gingival hyperplasia, hirsutism, hypomagnesaemia
Less diabetogenic than tacrolimus
Same CYP3A4 drug interactions; grapefruit interaction

⚠CNI Nephrotoxicity: Rising creatinine does NOT always mean rejection. Always check tacrolimus level first — supratherapeutic levels cause vasoconstriction and acute tubular injury. Reduce dose and reassess before biopsy in some cases.

🧪Antiproliferative Agents & Steroids

Mycophenolate Mofetil (MMF / CellCept)

Mechanism: inhibits IMPDH → blocks purine synthesis → lymphocyte antiproliferation
Dose: 500–1500mg BD (renally adjusted)
Side effects: GI (diarrhoea, nausea, cramping), leucopenia, anaemia
Teratogenic — contraception mandatory
No routine level monitoring in most centres

Azathioprine (Imuran)

Older alternative to MMF; purine analogue
Metabolised by TPMT — check TPMT enzyme before starting
TPMT deficiency → severe bone marrow toxicity
Allopurinol interaction: LIFE-THREATENING — dose reduce to 25%
Monitor FBC weekly initially

Corticosteroids

IV methylprednisolone intraoperatively (500mg–1g)
Oral prednisolone: typically start 20mg/day, taper over months
Many centres now use steroid minimisation/withdrawal protocols
Side effects: PTDM, HTN, osteoporosis, Cushingoid features, mood changes, infection
Provide bone protection (calcium, vitamin D, bisphosphonate)

🎯mTOR Inhibitors

Sirolimus (Rapamycin, Rapamune) & Everolimus (Certican)

Mechanism: inhibit mTOR → block T/B cell proliferation and cytokine signalling
Anti-proliferative: useful in post-transplant malignancy
Can allow CNI minimisation → nephroprotective strategy
Everolimus used in liver Tx — Certican allows CNI reduction
Monitor trough levels (sirolimus 4–12 ng/ml; everolimus 3–8 ng/ml)

mTOR Side Effects

Hyperlipidaemia (treat with statins — avoid simvastatin)
Impaired wound healing — avoid in early post-op period
Oral ulcers / mucositis
Proteinuria — check urine protein:creatinine ratio
Interstitial pneumonitis (rare, serious)
Thrombocytopenia, anaemia

🔥Rejection Treatment Protocols

Rejection Type	First Line	Second Line	Monitoring
Mild ACR (Banff 1)	Pulse methylprednisolone 500mg IV × 3 days	Increase maintenance immunosuppression	Daily creatinine; repeat biopsy at 6–8 weeks
Moderate-severe ACR (Banff 2–3)	Methylprednisolone 500–1000mg × 3 days	ATG (Thymoglobulin) 1.5mg/kg/day × 5–10 days	FBC daily (ATG lymphopenia), CMV prophylaxis
Steroid-resistant ACR	ATG as above	Consider switching CNI or adding belatacept	Close monitoring, nephrology/hepatology review
Active AMR	IVIG 2g/kg + plasmapheresis × 5 sessions	Rituximab 375mg/m²; bortezomib; eculizumab	DSA titres, C4d biopsy, daily function tests

ℹATG nursing precautions: Premedicate with antihistamine, paracetamol, and methylprednisolone 30 min before. Infuse via central line over 4–6h. Monitor for cytokine release (fever, rigors, hypotension) hourly. Restart CMV prophylaxis.

🦠Infection — Prophylaxis & Monitoring

Pathogen	Prophylaxis	Duration	Monitoring
CMV (Cytomegalovirus)	Valganciclovir (D+/R- = 6 months; R+ = 3 months; D-/R- = none routine)	3–6 months	CMV PCR monthly; monitor for valganciclovir-induced leucopenia
PCP (Pneumocystis jirovecii)	Cotrimoxazole (Trimethoprim-Sulfamethoxazole) 480mg OD	Minimum 6–12 months; lifelong if heavy immunosuppression	Clinical; check G6PD in high-risk populations before starting
Fungal (Candida, Aspergillus)	Fluconazole 50–200mg OD (liver Tx: higher risk); nystatin oral suspension (mouth)	1–3 months	Invasive fungal infection screen if febrile; Aspergillus galactomannan if high risk
HSV / VZV	Aciclovir (if CMV D-/R-); covered by valganciclovir if CMV prophylaxis used	3–6 months	Clinical recognition; early treatment
Bacterial	Perioperative cephalosporin; consider targeted prophylaxis based on local flora	24–48h surgical prophylaxis	Early sepsis screening; cultures before antibiotics

⚠Infection Risk Timeline: Month 1 — surgical/nosocomial infections. Months 1–6 — opportunistic infections (PCP, CMV, fungal) peak. After 6 months — community infections, late viral (EBV-related PTLD).

🩸Metabolic Complications

Post-Transplant Diabetes Mellitus (PTDM)

Occurs in 15–30% within 1 year
Caused by: tacrolimus (most diabetogenic), steroids, pre-existing risk factors
Screen with fasting glucose and HbA1c at 3, 6, 12 months
OGTT recommended if fasting glucose 5.6–7.0 mmol/L
Management: steroid reduction, switch tacrolimus → cyclosporin if possible, metformin (caution with eGFR), insulin
PTDM increases mortality and graft loss risk

Hypertension & Dyslipidaemia

Hypertension: >70% of transplant recipients — CNI-mediated vasoconstriction
Target BP: <130/80 mmHg (proteinuric patients: <125/75)
Preferred agents: CCBs (amlodipine — also counters CNI vasoconstriction)
Avoid ACEi/ARBs early post-op if eGFR unstable or hyperkalaemia risk
Dyslipidaemia: statins first-line; avoid simvastatin with CNI (myopathy risk) — use pravastatin or fluvastatin
Cardiovascular disease = leading cause of death with functioning graft

🎗Post-Transplant Malignancy

Skin Cancer

Most common post-transplant malignancy (up to 50× general population risk)
Predominantly squamous cell carcinoma (SCC) — more aggressive than in general population
Especially high risk in GCC — intense UV exposure, fair-skinned expatriates
Annual dermatology review mandatory
Sun protection counselling: SPF50+, protective clothing, avoid midday sun
Consider switching to mTOR inhibitor — anti-tumour properties

PTLD (Post-Transplant Lymphoproliferative Disorder)

EBV-driven B-cell proliferation; risk highest in EBV D+/R- (especially children)
Incidence 1–3% (kidney), up to 5% (heart/lung)
Presents: fever, lymphadenopathy, tonsillar enlargement, GI symptoms
Diagnosis: CT, PET, biopsy
Management: reduce immunosuppression first; rituximab; chemotherapy if aggressive lymphoma
Monitor EBV PCR in high-risk recipients

📋Medication Non-Compliance

🚨Non-compliance is the leading preventable cause of late acute rejection and graft loss. Rates of 20–50% reported in long-term follow-up studies.

Risk Factors for Non-Compliance

Adolescents and young adults
Psychiatric comorbidity / depression
Polypharmacy burden / side effects
Lack of social support
Language barriers (especially relevant in GCC expatriates)
Cost of medications in some GCC countries for non-citizens
Ramadan — altered medication timing disruption

Nursing Strategies

Structured transplant education pre- and post-op
Pill organisers and mobile app reminders (e.g., TransplantHero)
Simplified once-daily regimens where possible (Advagraf for tacrolimus)
Regular adherence assessment at every clinic visit
Motivational interviewing techniques
Involve family and social support
Pharmacy liaison and medication subsidies where available

🌙Organ Donation in the GCC — Overview

⚠GCC Donation Challenge: Deceased organ donation rates remain among the lowest globally (0.5–3 pmp vs 15–40 pmp in Spain/USA). Living donor programmes are the cornerstone of transplantation across the region.

Religious & Cultural Considerations

Islamic scholarly opinion on brain death varies — some scholars do not accept brain death as true death
Fatwa issued by the Islamic Fiqh Academy (1985) permitting organ donation in principle
Saudi Arabia's Supreme Council of Ulema: supports deceased donation with family consent
Family refusal remains the primary barrier — cultural belief in bodily sanctity after death
Opt-in systems in all GCC countries (no opt-out / presumed consent)
Faith-sensitive communication by nursing team is essential

Living Donor Prevalence

Living donor kidney transplants: 60–80% of all kidney transplants in GCC
Living donor liver transplantation (LDLT): growing; Saudi, UAE, Kuwait centres of excellence
Emotionally directed donation (family) is the norm
Non-directed altruistic donation: very rare culturally
Paired kidney exchange programmes: emerging in Saudi Arabia
Nurse role: living donor psychosocial assessment, education and follow-up

🏛Regulatory Bodies

Saudi Center for Organ Transplantation (SCOT)

Established 1986 — one of the oldest organ procurement organisations in the Arab world
Manages deceased donor identification, allocation and distribution nationally
Maintains Saudi transplant waiting list
Regulates all transplant centres in Saudi Arabia
Website: scot.org.sa — publishes annual activity reports
Accreditation requirements for transplant nursing staff

UAE: Dubai Organ Donation Committee & DOH

Dubai Health Authority (DHA) oversees transplantation in Dubai Emirate
Abu Dhabi Department of Health regulates SEHA transplant programmes
Federal Law No. 5/2016 — regulates organ transplantation nationally
Organ donation cards available through DHA
Other GCC: Kuwait (NORA), Bahrain (NBTC), Qatar (Hamad Medical), Oman (DGOT)

⚖Legal Framework — Organ Trafficking

🚨Organ trafficking is a serious criminal offence in all GCC states. Nurses must be alert to indicators of commercial donation and report concerns through hospital governance and regulatory channels.

Saudi Arabia: Human Organ Transplantation Act — prohibits commercialisation; criminal penalties including imprisonment
UAE Federal Law No. 5/2016: explicit prohibition of organ sale; applies to citizens and expatriates
Kuwait, Qatar, Bahrain, Oman: similar legislation criminalising organ commerce
Red flags: donor-recipient relationship inconsistencies; large financial transactions; coercion indicators; medical tourism facilitators
Istanbul Declaration (2008): GCC countries are signatories — prohibits transplant tourism

🌍Expatriate Patient Rights in GCC Transplantation

Access to Transplantation

Most GCC deceased donor waiting lists are restricted to citizens
Expatriates generally may only receive living donor transplants in GCC
Saudi Arabia: SCOT waiting list primarily Saudi nationals
UAE: select expatriate access in certain centres with specific criteria
Expatriates advised to consider home country transplantation
Medical insurance portability for transplant follow-up: a significant issue

Nursing Considerations for Diverse Populations

GCC nursing workforce >70% expatriate — multilingual capability is an asset
Interpreter services essential for informed consent in Arabic, English, Urdu, Tagalog
Cultural humility in discussing death/organ donation with patients' families
Awareness of South Asian genetic susceptibility to PTDM
Halal medication considerations (gelatin capsule formulations — tacrolimus)
Immigration status changes can affect treatment continuity — plan proactively

🌙Ramadan — Immunosuppression Considerations

ℹTransplant recipients who wish to fast during Ramadan require careful planning. Interrupting or erratically timing immunosuppression is a rejection risk. Individualised assessment is mandatory before Ramadan.

Challenges

Fasting hours 12–16h depending on GCC country and season
Tacrolimus and cyclosporin require strict 12-hourly timing (BD) or consistent 24h timing (OD)
Altered meal times affect drug absorption (especially cyclosporin — fatty meal dependent)
Dehydration risk — increases CNI nephrotoxicity
Drug timing shift can create supratherapeutic or subtherapeutic troughs

Nursing Guidance & Strategies

Discuss Ramadan plans at least 4 weeks before Ramadan begins
Early post-transplant (<1 year): strongly advise against fasting; consult transplant team
Stable, long-term recipients (>1–2 years): assess individually with transplant physician
Switch to once-daily Advagraf (extended-release tacrolimus) before Ramadan if appropriate
Dose timing: Iftar + Suhoor if BD regimen must continue
Increase monitoring frequency during Ramadan: weekly tacrolimus levels and creatinine
Ensure adequate fluid intake at non-fasting hours
Islamic scholars permit missing fast for medical necessity — provide supporting letter if needed

Tacrolimus Toxicity Risk Checker

Tacrolimus Trough Level (ng/ml)

Creatinine Change from Baseline (%)

Months Post-Transplant

Symptoms Present?

Rejection Risk Timeline Checker

Days Post-Transplant

⏱Transplant Rejection Timeline

Minutes to Hours (Intraoperative)

Hyperacute Rejection

Preformed antibody-mediated. Graft becomes mottled/cyanotic on table. Prevented by crossmatch. No treatment — nephrectomy.

Day 1–7

Surgical Complications Peak

Vascular thrombosis (HAT/RVT), primary non-function, urine leaks, bleeding. ICU monitoring, daily Doppler USS.

Day 5–90 (Peak: Day 7–30)

Acute Cellular Rejection (ACR)

T-cell mediated. Rising creatinine/LFTs, fever, graft tenderness. Biopsy confirms. Responds to pulse steroids in ~80%.

Month 1–6

Opportunistic Infections Peak

CMV, PCP, fungal infections. Highest immunosuppression burden. All prophylaxis must be in place and compliant.

Month 6–12

Metabolic Complication Emergence

PTDM, hypertension, dyslipidaemia screening. Steroid taper continuing. Late ACR still possible if non-compliant.

Year 1–5

Chronic Rejection / IFTA Risk

Gradual proteinuria, rising creatinine, hypertension. CNI nephrotoxicity compounds. Optimise all modifiable risk factors.

Year 5+

Malignancy & Cardiovascular Disease

Skin SCC, PTLD, cardiovascular events are leading causes of death with functioning graft. Annual dermatology, cardiology review.

📝Self-Assessment — 10 MCQs

Select an answer to receive instant feedback. Results track your score below.

Q1. A kidney transplant recipient on tacrolimus presents 10 days post-op with rising creatinine, fever and graft tenderness. Biopsy shows interstitial inflammation i3, tubulitis t2. What is the Banff grade and first-line treatment?

Q2. A patient post-living-donor kidney transplant on Day 1 has urine output of 0.4 ml/kg/h. The Foley catheter is patent, CVP is 6 cmH₂O, MAP is 62 mmHg. What is the PRIORITY nursing intervention?

Q3. Which complication is described as the "most feared early complication" following liver transplantation and requires urgent Doppler USS?

Q4. A transplant nurse is about to draw a tacrolimus trough level on a patient receiving tacrolimus 4mg BD (twice daily). When should the sample be taken?

Q5. A patient is prescribed azathioprine and is also started on allopurinol for gout. What is the MOST important nursing action?

Q6. In the GCC context, what is the PRIMARY reason for the very low deceased organ donation rates compared to Western countries?

Q7. A liver transplant recipient on Day 2 develops sudden cessation of bile from the T-tube, rising AST to 3000 U/L, and an INR rising to 2.8. What is the most likely diagnosis?

Q8. Which prophylaxis agent is used for Pneumocystis jirovecii (PCP) prevention in transplant recipients, and what baseline check is important in GCC populations?

Q9. A stable kidney transplant patient (18 months post-transplant) on tacrolimus 3mg BD approaches you to ask about fasting during Ramadan. What is the BEST nursing response?

Q10. Post-transplant malignancy is a major long-term concern. Which type is MOST common and what is the key preventive nursing intervention, especially in GCC?

Questions answered: 0 / 10

correct answers